|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||314.16 - 323.85|
|52 Week Range||249.17 - 388.67|
|Beta (3Y Monthly)||1.53|
|PE Ratio (TTM)||22.40|
|Earnings Date||Oct 23, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||390.88|
Biogen and UCB continue to further evaluate these data while assessing potential next steps. Dapirolizumab pegol is an investigational anti-CD40L pegylated Fab being developed in systemic lupus erythematosus (SLE) jointly by UCB and Biogen.
When drugmaker Biogen Inc. releases third-quarter earnings, scheduled for before the open on Tuesday, other major events for the company could well overshadow the financials. Chief among them is the company’s upcoming Alzheimer’s disease results, for the buzzed-about therapy BAN2401, which Biogen (BIIB) and partner Eisai (JP:4523) are set to present at an European conference this week. Call it financial déjà vu: The last time BAN2401 results were coming up, around Biogen’s second-quarter earnings, Wall Street analysts spent much of the company’s conference call asking about the trial.
On Tuesday, Biogen (NASDAQ: BIIB ) will release its latest earnings report. Benzinga's outlook for Biogen is included in the following report. Earnings and Revenue Analysts covering Biogen modeled for ...
"The path they're pursuing just seems to me to have too much risk," Baird analyst Brian Skorney told the Business Journal.
(Bloomberg) -- Beaten-down biotech stocks have a lot riding on the third-quarter earnings season, which kicks off Tuesday when Biogen Inc. reports.
Biotech stocks are staging a rebound following the losses incurred in the week ended Oct. 12 amid catalysts that include the third-quarter earnings season and presentations at the European Society of Medical ...
On the third-quarter call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.
Wall Street analysts expect Biogen’s (BIIB) third-quarter revenues to increase ~8.2% to $3.33 billion—compared to its revenues of $3.07 million during the third quarter of 2017. Biogen’s stock price has decreased nearly 4.1% in the last 12 months. Analysts’ recommendations show a 12-month target price of $390.88 per share—compared to the last price of $330.15 per share as of October 18.
As we discussed in the previous part, analysts expect Biogen’s (BIIB) revenues to increase 8.3% to $3.33 billion during the third quarter. Biogen’s product portfolio includes multiple sclerosis products, spinal muscular atrophy products, biosimilars, and other products. Biogen’s portfolio also includes Anti-CD20 therapeutic programs.
Biogen (BIIB), a leading biotechnology company, is scheduled to release its third-quarter earnings on October 23. Analysts expect the adjusted EPS to be $6.78 on revenues of $3.33 billion during the third quarter.
Procter & Gamble PG – The consumer products giant reported adjusted quarterly profit of $1.12 per share , exceeding estimates by 3 cents a share. Revenue also came in above Street forecasts and the company posted organic sales growth of 4 percent for its fiscal first quarter. Honeywell HON – Honeywell earned an adjusted $2.03 per share for the third quarter , 4 cents a share above estimates.
EMBARGOED FOR DISTRIBUTION Please note CTAD embargo policy: All materials submitted to CTAD are embargoed for publication and broadcast until the officially scheduled date and time of presentation, symposia or poster session. CAMBRIDGE, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Biogen (BIIB) announced it will present data from its Alzheimer’s disease (AD) clinical development portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) annual meeting in Barcelona, Spain (October 24-27).
The honorees include several MIT researchers and the developers of a drug sold by Cambridge-based Biogen.
LONDON (Reuters) - South Korea's Samsung Bioepis and its partner Biogen (BIIB.O) have launched a third rival to AbbVie's (ABBV.N) blockbuster medicine Humira in Europe, ramping up competition for a slice ...
South Korea's Samsung Bioepis and its partner Biogen have launched a third rival to AbbVie's blockbuster medicine Humira in Europe, ramping up competition for a slice of the world's top-selling prescription drug's sales. A fourth so-called biosimilar copy of Humira is expected soon from Mylan . The primary European patent on Humira expired on Oct. 16, opening the door to cheaper near-identical copies for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis.
CAMBRIDGE, Mass. & INCHEON, Korea-- -- IMRALDI TM , a biosimilar referencing HUMIRA ® i , is the third anti-TNF biosimilar developed by Samsung Bioepis to be commercialized by Biogen across Europe, following BENEPALI TM and FLIXABI TM Biogen and Samsung Bioepis were the first in Europe to receive approvals for biosimilars referencing the three most prescribed anti-TNF medicines in Europe. Biogen and ...
IMRALDITM is approved in the European Union for the same 14 complex autoimmune conditions as its reference product In 2017 Biogen became the first company in Europe with.
Of the 23 analysts covering Sarepta Therapeutics (SRPT) in October, eight analysts gave the stock a “strong buy” rating, 14 analysts gave it a “buy” rating, and one analyst gave Sarepta Therapeutics a “hold” rating.
Sarepta Therapeutics (SRPT) has a sponsored research and exclusive license option agreement with Genethon for advancing the latter’s microdystrophin gene therapy program. Sarepta also has a sponsored research and exclusive license option agreement with Duke University for advancing its gene-editing CRISPR/Cas9 technology for muscular dystrophy. Sarepta had submitted a marketing authorization application (or MAA) for eteplirsen to the European Medicines Agency (or EMA) in November 2016.
Sarepta Therapeutics (SRPT) is working with several strategic partners for developing multiple treatment approaches to DMD. These partners include Nationwide Children’s Hospital, Myonexus, Genethon, Duke University, and Summit Limited.
Sarepta Therapeutics’ (SRPT) Exondys 51 uses exon-skipping technology to skip exon 51 of the DMD gene. The drug is designed to bind to exon 51, which leads to an exclusion or skipping of this exon during mRNA processing. Golodirsen uses exon-skipping technology to skip exon 53 of the DMD gene.